BORUZU, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma, launched April 8, 2025
Calquence plus chemoimmunotherapy recommended for approval in the EU by CHMP for 1L MCL April 2, 2025
Update relating to Resminostat’s (Kinselby) Marketing Authorisation Application announced March 18, 2025
U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia March 18, 2025
Clinical Trial Application Submitted in Australia for CS5001 in Combination with 1L SOC for DLBCL March 11, 2025
First Dose Cohort in STARLIGHT-1 Trial Completed and Approval Received to Initiate Higher Dose Cohort March 4, 2025
EPKINLY® (epcoritamab) Approved by Japan MHLW for Additional Indication as a Treatment for R/R Follicular Lymphoma February 25, 2025
Positive Topline Results for Breyanzi® (lisocabtagene maraleucel) in Adult Patients with R/R MZL Announced February 19, 2025
Ph 3 waveLINE-010 Trial of Zilovertamab Vedotin for the Treatment of 1L DLBCL Patients initiated February 11, 2025
FIRCE-1 Ph 2 Study of Firi-cel to Discontinue; Advances Remaining Programs While Evaluating Strategic Options February 4, 2025
Calquence plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma January 21, 2025
HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage CTCL January 21, 2025
Type II variation application submitted to the EMA seeking approval of IMBRUVICA in adult patients with 1L MCL eligible for auto SCT December 25, 2024
U.S. FDA Fast Track Designation for NX-5948 for the Treatment of R/R Waldenstrom’s Macroglobulinemia December 25, 2024
